Retigabine (RGB) is an investigational antiepileptic drug, which undergoes extensive UGT1A1, 1A9 and 1A4-mediated N-glucuronidation and Nacetylation. The mono-acetylated metabolite of RGB has some pharmacological activity and is denoted AWD21-360. We investigated whether the pharmacokinetics (PK) of RGB and AWD21-360 are altered in subjects with Gilbert's syndrome (GS) and/or with frequent N-acetyltransferase 2 (NAT2) slow acetylator (SA) polymorphisms. Based on consistent genotyping and phenotyping screening results, 37 Caucasian subjects (21-46 years; 31 men, six women) were assigned to one of the following groups:
Introduction
Gilbert's syndrome (GS) is a mild congenital non-hemolytic unconjugated hyperbilirubinemia, which is as frequent as 10-13% in western European Caucasian populations. [1] [2] [3] GS is functionally characterized by reduced expression of the hepatic bilirubin UDP-glucuronyltransferase 1A1 (UGT1A1) by about 30%.
Subjects with GS have a normal coding region for the UGT1A1 gene, but show homozygousity for two extra bases (TA) in the TATAA element of the 5 0 promoter region of the gene, that is, A(TA)7TAA instead of the normal A(TA)6TAA configuration. [1] [2] [3] The longer TATAA element results in reduced transcription of the gene. Although (TA)7 is the only polymorphic allele associated with GS in the Caucasian population, additional (TA)5 and (TA)8 variants were found in GS individuals of African origin. 4 From a clinical perspective, GS is frequently regarded as a harmless variant in the individual genetic make-up of affected individuals. However, there is growing awareness that GS may affect drug glucuronidation and could be associated with unexpected adverse drug reactions. 5 Impaired drug glucuronidation capacity in carriers of GS may even result in serious drug toxicity, as evidenced by published case reports for irinotecan (CPT-11). 6, 7 The clinical significance of N-acetyltransferase 2 (NAT2) slow acetylation polymorphisms is well established for a number of drugs, including isoniazid, hydralazine, dapsone, procainamide and sulfoniazide. Increased risks for various types of adverse drug reactions in slow acetylators (SAs) of NAT2, such as nephrotoxicity and peripheral neuropathy due to isoniazid therapy, increased hypersensitivity to sulfonamines as well as systemic lupus erythematosus following isoniazid, procainamide, and hydralazine are well acknowledged. 8, 9 The prevalence of functional NAT2 slow acetylation polymorphisms is approximately 50% in Caucasians and African Americans and about 10% in subjects of Asian descent. 10 Retigabine (RGB) is a first in class investigational antiepileptic drug, which acts as specific neuronal M-current potassium channel opener (KCNQ2/3 and KCNQ3/5 channels). [11] [12] [13] [14] [15] [16] [17] [18] [19] RGB further enhances gamma amino butyric acid (GABA)-evoked currents in a concentration-dependent fashion. These effects, however, require much higher concentrations to become effective. 20, 21 Recently, the antiepileptic efficacy of RGB was confirmed in patients with partial epileptic seizures. 22 The drug is predominantly metabolized by N-glucuronidation resulting in the formation of two N-glucuronides and to a considerably smaller extent by N-acetylation to form a pharmacologically less active N-acetyl derivative denoted AWD21-360 ( Figure  1) . 23, 24 AWD21-360 also undergoes glucuronidation similar to RGB ( Figure 1 ). RGB is not subject to any metabolism by cytochrome P450 enzymes. 24 Based on in vitro studies using monoclonal human UGTs the UDP-glucuronosyltransferase (UGT) isozymes 1A1, 1A9, 1A4 and to a smaller extent 1A3 were found to catalyze the N-glucuronidation of RGB. However, some inconsistent findings on the relative Retigabine PK in Gilbert's syndrome and NAT2 polymorphisms R Hermann et al contributions of these UGTs to RGB's N-glucuronidation have been reported by two independent working groups. 25, 26 Furthermore, predictions from in vitro data on the relative metabolic contributions of single enzymes in vivo is generally difficult and often unreliable.
RGB pharmacokinetics (PK) in healthy young subjects are characterized by rapid absorption (t max 1.6 h), a clearance of 0.58 l/h/kg, a volume of distribution of 6.2 l/kg, low plasma protein binding (about 80%), and terminal plasma half-life times of approximately 8.5 h. 27, 28 Absolute bioavailability (F) of RGB oral immediate release dosage forms is about 60% (95% confidence interval (CI) 49-75%). 22, 28 RGB shows linear PK in adult healthy subjects up to 350 mg single and b.i.d. repeated oral doses. 29 In patients with epilepsy, dose linearity of RGB has been demonstrated up to 1200 mg/ day. 22 The mono-acetylated metabolite AWD21-360 is rapidly formed and cleared at the same rate as RGB. 29 Notably in subjects of African descent, the clearance and volume of distribution of RGB is 25 and 30% lower, respectively. 22 This finding is consistent with previously described ethnic differences in N-glucuronidation.
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Based on the currently available knowledge of RBG's metabolic pathways and the principal enzymes involved, the primary objective of this combined pharmacogenetic/PK study was to evaluate whether the PK of RGB and its monoacetylated metabolite, AWD21-360, may be altered in carriers of GS who are either rapid or SAs relative to healthy non-GS individuals with corresponding acetylator status. A secondary objective was to evaluate the repeated dose safety and tolerability of RGB in the described populations.
Results
In Table 1 , subject's demographic data including fasting morning serum bilirubin baseline values are shown. No statistically significant differences in age and body weight were noted between groups, whereas mean total serum bilirubin concentrations were 88 and 45% higher in GS subjects than in non-GS subjects with corresponding rapid acetylator (RA) and SA status, respectively (P ¼ 0.0098 for GS/RA compared with non-GS/RA; P ¼ 0.0187 for GS/SA compared with non-GS/SA, and P ¼ 0.0004 for all GS subjects compared with all non-GS subjects). Both GS groups showed mean bilirubin values 420 mmol/l at baseline.
The mean (7s.d.) total serum bilirubin AUC 0-24 values obtained during the drug-free 24 h fasting test (400 kcal diet) were 377787 and 3947121 mmol/l h in the non-GS/RA and non-GS/SA groups, but 7467276 and 7507232 mmol/l h in the GS/RA and GS/SA groups, respectively, thus confirming the significant group contrasts between GS and non-GS subjects already seen in total fasting morning serum bilirubin concentrations.
The single-dose PK of RGB and AWD21-360 were consistent with previous studies in healthy subjects and did not show any significant group differences for geometric mean peak plasma concentrations (C max ), systemic exposure (AUC) or apparent oral clearance (CL/F). Single-dose data are therefore not presented in further detail.
In course of the multiple-dose treatment, RGB and AWD21-360 steady state has been achieved in all groups at day 3: mean (7s. C max , AUC, and CL/F data are geometric mean (95% confidence interval). t max and t 1/2 data are median (range). Retigabine PK in Gilbert's syndrome and NAT2 polymorphisms contrasts of exposure results are consistent no matter whether AUC t,ss raw data or body weight normalized AUC t,ss data are considered. The respective plasma concentration-time profiles are illustrated in Figures 2 and 3 . Notably, most of the median profiles show second peak phenomena as do many individual curves (not shown), which is believed to reflect the enterohepatic circulation of RGB as described previously. 25 The summary of the statistical evaluation (point estimates and 95% CI derived from two-way ANOVA) for the non-GS/ GS and RA/SA ratios for multiple-dose AUC and C max values of RGB and AWD21-360 are summarized in Tables 4 and 5 , respectively. For RGB no statistically significant differences in the primary PK parameter estimates could be noted between GS and non-GS subjects and between RA and SA subjects, respectively. For AWD21-360, RA subjects showed a Retigabine PK in Gilbert's syndrome and NAT2 polymorphisms significantly higher total exposure of about 32% (95% CI 101.9-172.5) relative to SA subjects (P ¼ 0.0362). The UGT1A1 metabolic capacity (i.e. presence or absence of GS), however, did not significantly affect the overall exposure to AWD21-360. RGB was generally well tolerated. There were no serious or unexpected treatment emergent adverse events (TEAEs), no premature study discontinuations due to adverse events, and no clinical relevant changes in vital signs, clinical safety laboratory or ECG variables. In particular, there were no significant bilirubin increases noted in course of the study. There were no statistically significant differences in the TEAE frequencies between any groups, a finding which is consistent with the lack of significant exposure differences for RGB between groups. Most TEAEs with assumed treatment causality consisted of mild/moderate and transient CNS-related symptoms that were reported with the following preferred terms and frequencies: Vertigo (20/37, 54.1%), fatigue (13/37, 35.1%), concentration impairment (12/37, 32.4%), asthenia (5/37, 13.5%), paraesthesia (5/37, 13.5%), vision abnormal (5/37, 13.5%), dizziness (5/37, 13.5%), ataxia (4/37, 10.8%), headache (3/37, 8.1%) and coordination abnormal (3/37, 8.1%).
Discussion
Glucuronidation is an important pathway for human drug metabolism. Only few drugs, however, have been investigated for potential PK alterations in subjects with GS, or for their ability to interact with the glucuronidation of endogenous substrates such as bilirubin. Recently, the PK of morphine was found unaltered in GS subjects, most probably because morphine glucuronidation is predominantly catalyzed by UGT2B7 with only minor contribution of UGT1A1 to the formation of morphine-3-glucuronide. 31, 32 Although for paracetamol a reduction in urinary glucuronidation products and a shift towards oxidation products was suggested for a phenotypically defined subgroup of GS subjects, overall GS individuals showed no significant impairment in paracetamol metabolism as compared with healthy controls. 33 This is consistent with a recent report suggesting that paracetamol glucuronidation is predominantly mediated by UGT1A9, with additional contributions of UGT1A1 and UGT1A6. 34 Total lorazepam clearances, in contrast, were found 20-40% lower in subjects with GS compared with non-GS individuals. 35 Another welldocumented example of a clinically relevant drug interaction associated with GS is the increased toxicity of the topoisomerase I inhibitor irinotecan. In this case, the active metabolite of irinotecan (SN-38) is inactivated through glucuronidation by UGT1A1. 36 Severe toxicity in terms of grade 4 neutropenia and diarrhea in course of irinotecan therapy has been described in two cancer patients with GS, and a significant trend towards a decrease in SN-38 and bilirubin glucuronidation was shown in human liver tissue of GS individuals. 6, 37 A second example of unexpected drug toxicity is a severe speech disorder following concomitant olanzapine and lorazepam treatment in a young male psychiatric patient with GS, which points to the importance to also consider potentially additive adverse drug effects on the metabolic function of UGT1A1 in GS. 38 Other drugs, such as tranilast and indinavir have been shown to induce hyperbilirubinemia in about 12 and 25% of treated patients, respectively, apparently by direct inhibition of UGT1A1. 39, 40 Individuals with GS were shown to be most susceptible to these drug-induced hyperbilirubinemias. 39 These examples highlight the importance to carefully consider potential alterations in drug metabolism and safety as well as impairment of bilirubin glucuronidation in subjects with GS. Clinical studies should be considered for drugs that may be inhibitors of UGT1A1 or may rely on glucuronidation by UGT1A1 to a relevant extent. The latter was our rationale to design the present study with RGB.
It is one of the key outcomes of our study, that the PK of RGB is not altered even when the two polymorphic metabolic pathways UGT1A1 and NAT2 are concomitantly affected. Our data suggest that N-acetylation is capable to partially compensate for the metabolic incapacity of GS individuals, because an increase in the acetylation product AWD21-360 was consistently observed in subjects with GS relative to non-GS subjects, regardless of their acetylator status. However, because the formation of AWD21-360 in the GS/SA group did not achieve the exposure seen in the GS/RA groups, additional compensatory metabolic mechanisms are likely to be present. As the N-glucuronidation of RGB is not only catalyzed by UGT1A1 but also by UGT1A9, UGT1A4 and perhaps by UGT1A3, it is reasonable to assume that these UGTs are also capable to compensate for the metabolic incapacity related to the genetic polymorphisms of UGT1A1, NAT2, or both. It should be further noted, that the known enterohepatic circulation of RGB 25 could potentially shadow existing differences in the overall metabolic capacity, as it has also been suggested for the disposition of lorazepam in patients with GS. 35 While neither GS nor the NAT2 acetylator status or both were shown to alter the PK of RGB parent drug, the NAT2 acetylator status was shown to have a significant impact on the exposure of subjects to the mono-acetylated metabolite AWD21-360. Mean steady-state trough concentrations of AWD21-360, for instance, were between 26 and 33% lower in slow acetylating GS subjects than in the other groups. Further, the total exposure (AUC) to AWD21-360 was significantly higher in the RA groups than in the SA groups (Table 5 ; P ¼ 0.0362). Because AWD21-360 is pharmacologically distinctly less active than RGB, the exposure differences of this metabolite do not have a clinical meaning in terms of safety and efficacy, which is consistent with the lack of statistically significant differences in the treatment emergent adverse event frequencies and patterns between any of the groups. Finally, our study suggest that RGB is unlikely to inhibit UGT1A1 in vivo because the 24-h total serum bilirubin was found to be unaltered in course of RGB multiple dose treatments, when compared to 'drug-naïve' bilirubin group differences at screening.
In conclusion, the PK of RGB was found to be unaltered in GS individuals, in subjects with frequent NAT2 slow acetylation polymorphisms, and in carriers of both polymorphic variants. The exposure to the mono-acetylated metabolite AWD21-360, however, was significantly related to the NAT2 acetylator status. Metabolic switching to the mono-acetylated metabolite AWD21-360 may partially compensate for the impaired glucuronidation capacity in GS subjects.
Material and methods

Subjects and study design
This study was a single-center, combined single-/multipledose, open-label, pharmacogenetic/PK study in healthy young subjects with different genotypes and phenotypes for the two polymorphic drug metabolizing enzymes UGT1A1 and NAT2. Subjects were genotyped and phenotyped as described below. In case of consistent genetic and functional outcomes, subjects were assigned to one of the following four groups:
1. Absence of GS/RA (non-GS/RA), 2. GS/RA, 3. Absence of GS/SA (non-GS/SA), 4. GS/SA. Study participants were recruited from a Southern Germany subject's pool in which all subjects were genotyped for frequent NAT2 and UGT1A1 polymorphisms. 1 The phenotypic diagnosis of GS was obtained by means of a 24-h fasting test (400 kcal diet). 5 Throughout the fasting period total, unconjugated and conjugated bilirubin were determined every 2 h. The diagnosis of GS was concluded if total bilirubin rose to X25 mmol/l at least once during the 24 h fasting period.
NAT2 phenotyping was performed by administration of 200 mg caffeine (Coffeinum N 0.2 tablets, Merck, Darmstadt, Germany) and subsequent urine collection for 6 h. A specific LC-MS/MS method was used for the quantification of the caffeine metabolites 5-acetylamino-6-formylamino-3-methyluracil (AFMU), 5-acetylamino-6-amino-3-methyluracil (AAMU), 1-methylxanthine (1X), and 1-methylurate (1U). Details of the phenotyping protocol and the bioanalytical method of the caffeine metabolites including its actual performance data (accuracy and precision) in the measurement of samples derived from this study have been recently reported by Jetter et al. 41 In brief, NAT2 activity was determined by calculating urinary molar metabolic ratios of (AFMU þ AAMU)/(AFMU þ AAMU þ 1X þ 1U). 42 Metabolic ratios below 0.21 were defined as acceptance criterion to conclude an SA phenotype, whereas ratios X0.32 were required to conclude an RA phenotype. Subjects with intermediate ratios between these categories were considered not unequivocally classifiable and did not qualify for inclusion into the study.
Thirty-seven healthy young subjects (31 men/6 women) fulfilled the genotype and phenotype requirements as well as all other inclusion criteria, agreed to participate in the study and were enrolled. One female subject of the non-GS/SA group withdrew consent after completion of the single-dose part of study. Thus, multiple-dose data are available for 36 subjects. The study was conducted at the Clinical Pharmacology Unit of ASTA Medica AG (predecessor of VIATRIS GmbH & Co. KG), Frankfurt, Germany. Each subject gave written informed consent before participation in the study, which was approved by the institutional review board of the 'Landesärztekammer' Hessen. The study was conducted in accordance with the Declaration of Helsinki (Somerset West Amendment, 1996) and the ICH Guideline on Good Clinical Practice (Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95), January 17, 1997). All subjects were healthy according to medical history, physical examination and clinical laboratory data. Use of any OTC or prescription medication within 1 week before test drug administration or concomitant medication during the course of the study was not allowed. Alcoholic beverages and strenuous physical exercise were prohibited from 48 h before the first administration until collection of the last PK blood sample. On the single-dose and multiple-dose PK profiling days, subjects were confined in-house for a total of 36 h, from 12 h before until 24 h after the morning dose. During in-house confinement smoking, caffeine-containing food and beverages were prohibited, and standardized meals were served. During the ambulatory multiple-dose part of the study, caffeine intake was restricted to 2 cups/glasses and smoking to 10 cigarettes per day. On study day 1, each subject received a 200-mg single oral dose of RGB (2 capsules, 100 mg each) after an overnight fast of at least 10 h and was requested to continue to fast until 4 h after dosing. On study days 3-7, 200-mg oral doses of RGB were administered after overnight fasts in the morning (0700-0900 hours) and after 4 h fasting periods in the evening (1900-2100 hours). On study day 7, subjects fasted from at least 10 h before the morning dose until 4 h after the morning dose and the evening dose.
Genotyping of subjects DNA isolation from human blood samples. DNA was isolated from 5-ml ethylendiaminetetraacetic acid whole blood samples by using the DNA Extraction Kit NucleoSpin Blood (Macherey-Nagel, Germany) according to the manufacturer's instructions.
Genotyping of UGT1A1. TA inserts in the TATA box of the promoter of the UGT1A1 gene were identified by a polymerase chain reaction (PCR) method coupled with measurement of the fluorescence resonance energy transfer (FRET) as recently described elsewhere. 1 Genotyping of NAT2. After amplification with PCR, four single nucleotide polymorphisms, that is, nt 481 (C4T, KpnI,], nt 590 (GoA, TaqI), nt 803 (A4G, DdeI) and nt 857 (G4A, BamHI) of the NAT2 gene were determined using the aforementioned FRET method. The fluorogenic adjacent hybridization probes were designed according to guidelines recommended by Roche Diagnostics Inc. PCR primers were 5'-TGCATTTTCTGCTTGACA (sense primer) and 5 0 -GTT GGGTGATACATACACAA (antisense). Probes were designed so that their melting temperatures (Tm) were marginally higher than the Tm of the primer. The anchor probe of NAT2 c.481C4T was labelled with fluorescein (X) at the 3 0 end (5 0 -GCATTTTCTGCTTGACAGAAGAGAGAGGA-X-3 0 ) and the sensor probe was labelled with Lightcycler Red 640 (LCRed 640) at the 5 0 end (5 0 LC Red640-TCTGGTACC TGGACCAAATCAGGA phosphorylated). In the case of the NAT2 c.590G4A allele, the anchor probe was labelled with flourescein (X) at the 3 0 end (5 0 -ACGTCTGCA GGTATGTATTCATAGACTCAAAAT X-3 0 ) and the sensor was labelled with Lightcycler Red-640 (LC-Red 640) at the 5 0 end (5 LC-Red 640-TCAATTGTTCGAGGTTCAAGCGT phosphorylated). In the case of the NAT2 c.857G4A allele, the anchor probe was labelled with flourescein (X) at the 3 0 end (5 0 -TTCCTTGGGGAGAAATCTCGTGC X-3 0 ) and the sensor was labelled with Lightcycler Red-640 (LC-Red 640) at the 5 0 end (5 0 LC-Red 640-CAAACCTGGTGATGGATCCCT phosphorylated). Each of the corresponding probes recognized adjacent sequences with the shorter probe lying over the mutation site and the probes were separated by two bases or three bases. Fluorescein was used as the donor fluorophore and blocked extension from the probe during PCR. LC-Red 640 was used as the acceptor of the FRET process with its 3 0 end phosphorylated to block extension. Probes were synthesized by TIB MOLBIOL (Berlin, Germany). The greater stability of the longer anchor probe meant that loss of fluorescence occurred as the shorter probe melted off the template. PCR was performed with 0.32 mM NAT2 primers (see above) in a standard PCR reaction including 200 nM anchor and 200 nM hybridization probe, 100 ng DNA, 2.4 mM MgCl 2 and 2 ml Light Cycler DNA master hybridization mix in a total of 20 ml (Light Cycler-DNA Master Hybridisation Probes, Roche Diagnostics Inc., Germany). The reaction started at 951C for 2 min and amplification was performed for 45 cycles with a denaturation at 951C (0 s, ramp rate 201C/s), an annealing step at 451C (10 s, ramp rate 201C/s) and an extension step at 721C (20 s, ramp rate 201C/s). PCR product identification was made by analysis of DNA melting curves. DNA was therefore denaturated at 951C for 30 s and maximal fluorescence was acquired by holding the reaction at 401C for 30 s. Data were obtained by heating slowly to 801C with a ramp rate of 0.21C/s and collected continuously during that time. Fluorescence was converted to melting peaks by software supplied by the manufacturer (Roche Diagnostics), which plotted the negative derivative of fluorescence with respect to temperature (ÀdF/dT vs T). The sequence-specific hybridization probes melted off the target sequence at a characteristic temperature (601C (mutation) and 661C (wild type)) in the case of the NAT2 c.481C4T and NAT2 c.857G4A allele (channel F2 in the Light Cycler) and at 581C (variant allele) and 671C (reference allele) in the case of NAT2 c.590G4A (channel F2 in the Light Cycler). The variant alleles produced a shift in the melting temperature of about 61C allowing easy detection of a reference and variant allele.
PK blood sampling and analytical methods. Blood samples for RGB and acetylated metabolite plasma concentrations were collected in EDTA K-Monovette s tubes (2 Â 2.7 ml, Sarstedt, Germany), for single-dose profiling (day 1) predose, then 0. 33 A sensitive and specific high-performance liquid chromatography assay with tandem mass-spectrometry detection (HPLC/MS/MS) was used to determine the plasma concentrations of RGB and its mono-acetylated metabolite, AWD21-360 (Luna, Phenomenex s column, Phenomenex, Torrance, USA and an API 3000 system, PE Sciex, Toronto, Canada). The lower limit of quantification was 1.0 and 2.5 ng/ml for RGB and AWD21-360, respectively. Quality control consisted in daily construction of new plasma calibration lines between 1 and 1000 ng/ml and in coanalysis of spiked control plasma samples of 3, 15, 150 and 750 ng/ml. The analytical accuracy (percent deviation observed concentration from nominal concentration) and precision (coefficient of variation, %) of the assay was 1-6% and 10-15%. Only those analytical batches were accepted whose control sample accuracy did not exceed 15% (20% at the low concentration).
Further details of the method are described elsewhere. 43 The N-glucuronides of RGB could not be measured in that study because they have been previously shown to be instable in course of bioanalytical procedures and no internal standard is available.
Total serum bilirubin assessments and analysis. Blood samples were collected in 2.7 ml Serum Monovette s tubes (Sarstedt, Germany) in the morning after an overnight fast on screening, and every 2 h for 24 h during a drug-free fasting day (400 kcal diet) as well as for 24 h on study days 1 and 7 (normal diet). From blood collection until analysis, samples were stored in a closed light-opaque container. Blood was allowed to clot for at least 30 min and was then centrifuged (3600 r.p.m. for 10 min, Labofuge GL s , Heraeus). Two 500 ml aliquots of the resulting serum were transferred into clean polypropylene tubes. One tube was frozen immediately and stored at À201C (reserve sample). The serum in the other tube was analyzed for total bilirubin within 2 h after blood collection by a DPD method (Vitros 250, Ortho-Clinical Diagnostics, Neckargemuend, Germany). The upper limit of normal was 19 mmol/l. Total bilirubin area under the curve values (AUC 0-24 ) were calculated for 24 h periods using the trapezoidal rule.
Tolerability and safety. Safety assessments were based on reports of adverse events, routine physical examinations including blood pressure, pulse rate and ECG. Systolic and diastolic blood pressure and pulse rate were recorded in the supine position by oscillometry (Dinamap s , Criticon GmbH, Norderstedt, Germany) after the subjects had rested for at least 5 min. Blood pressure and pulse rate were recorded on days 1 and 7 predose, and 4 h after dosing. Twelve-lead ECG (Cardiosoft s , Marquette Hellige GmbH, Freiburg, Germany) readings were recorded on days 1 and 7 predose, and 4 h after dosing.
PK and statistical analyses. The PK analysis of RGB and its acetylated metabolite (AWD21-360) plasma concentrations was performed by model independent methods. 44 Values for the maximum concentration (C max ) and the time to reach C max (t max ) were obtained directly from the data. All PK calculations were performed with the validated Excel-based software (FUNCALC 2). 45 For single-dose PK the following variables were determined: C max , t max , t 1/2 , AUC 0-N , AUC 0-N, norm (normalized to a standard body weight of 70 kg), and CL/F (parent compound only). After examination of individual concentration-time profiles, at least three data points judged to be in the terminal phase were used to calculate the terminal rate constant (l z ) by log-linear regression. The terminal half-life (t 1/2 ) was estimated as ln 2/l z . The area under the concentration-time curve from zero to the last quantifiable concentration (C t last ) observed at time t last (AUC 0-t last ) was determined by the linear trapezoidal rule. The total AUC was calculated as AUC 0-t last þ C T /l z . Mean extrapolated parent drug's and metabolite's AUC portions were 4.5 and 6.8%, respectively. The apparent oral clearance (CL/F) was obtained as dose/ AUC. Plasma concentrations below the limit of quantification of the assay were set to a value of zero if they occurred before t max and were otherwise considered as missing values for the PK analysis. For multiple-dose PK, the following variables were determined: C max, ss , t max, ss , t 1/2, ss , AUC t, ss , AUC t, ss, norm (normalized to a standard body weight of 70 kg), and CLss/F (parent compound only).
The statistical analyses were performed using the General Linear Model procedure in SAS (version 6.12, SAS Institute, Inc.; Cary, NC, USA). A multiplicative model with factors UGT1A1 and NAT2 genotypes, the corresponding interaction term, and a log-normally distributed error term were fitted for AUC and C max . Point estimates and 95% CI of body weight corrected steady-state AUC and C max values were derived from two-way ANOVA. All tested hypotheses were two-sided and the a level was set at 0.05. As there were no interactions UGT*NAT, the factors UGT and NAT data can be interpreted independently.
Duality of interest
None of the authors has any financial or personal relationship to disclose that could potentially be perceived as influencing the described research.
